97144 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
#302Vaccine Compositions
#303Immuno-based botulinum toxin serotype A activity assays
#304Antibodies to toxins
#305Anti-botulism antibody coformulations
#306HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENOMICE
#307Neurotoxins exhibiting shortened biological activity
#308Inhibition of secretion from non-neuronal cells
#309Therapeutic composition comprising a botulinum neurotoxin
#310Engineered type IV pilin of
#311MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS
#312Antibody composition with altered Fab sialylation
#313Means and methods for manufacturing highly pure neurotoxin
#314Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction
#315Treatment of celiac disease with IgA
#316Compositions and methods for generating antibodies
#317Therapeutic composition comprising a botulinum neurotoxin
#318Antibodies that neutralize botulinum neurotoxins
#319Clostridial neurotoxins with altered persistency
#320Antibodies to spores and uses thereof
#321METHOD OF PROVIDING IMMUNOGLOBULIN SECRETING B LYMPHOCYTES AND HUMAN ANTIBODIES
#322Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
#323Subtype of neurotoxin type A and uses thereof
#324INHIBITION OF SECRETION FROM NON-NEURONAL CELLS
#325METHODS AND MATERIALS FOR GASTROINTESTINAL DELIVERY OF PATHOGEN/TOXIN BINDING AGENTS
#326Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
#327Methods and systems for multi-antibody therapies
#328High affinity human antibodies to PCSK9
#329Antibody Coformulations
#330Recombinant toxin fragments
#331Method for the detection and identification of a variant strain in a sample
#332Therapeutic clostridium difficile antibody compositions
#333Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody
#334Fusion partner cell line for preparation of hybrid cells expressing human antibodies
#335Method of making hybrid cells that express useful antibodies
#336Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
#337Method for Linking Sequences of Interest
#338BoNT/A Peptides and Methods of Predicting and Reducing Immunoresistance to Botulinum Toxin Therapy
#339Bont/a peptides and methodsof predicting and reducing immunoresistance to botulinum toxin therapy
#340Methods and systems for multi-antibody therapies
#341Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins
#342Cells useful for immuno-based Botulinum toxin serotype A activity assays
#343Antibodies against toxins and uses thereof
#344Antibodies against clostridium difficile toxins and uses thereof
#345Monoclonal antibodies that neutralize botulinum neurotoxin
#346Immuno-based botulinum toxin serotype A activity assays
#347Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
#348High affinity human antibodies to PCSK9
#349Botulinum antitoxin compositions and methods
#350Antibody producing non-human mammals
#351Methods for producing antibodies from plasma cells
#352Antibody producing non-human mammals
#353Rationally designed antibodies
#354Monoclonal antibody production by EBV transformation of B cells
#355Human antibodies derived from immunized xenomice
#356Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
#357MEDICAMENT FOR LCT POISONING
#358GENERATION OF HEAVY-CHAIN ONLY ANTIBODIES IN TRANSGENIC ANIMALS
#359Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
#360Method for isolation of soluble polypeptides
#361Human antibodies derived from immunized xenomice
#362Compositions and methods for generating antibodies
#363Rationally designed antibodies
#364Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
#365High-affinity monoclonal antibodies for botulinum toxin type A
#366STREPTAVIDIN-BIOTIN-LINK ANTIBODY-HAPTEN SYSTEM
#367Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
#368Oligosialic acid derivatives, methods of manufacture, and immunological uses
#369Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin A peptides
#370Host Cells Containing Multiple Integrating Vectors
#371Synthesis of human secretory IgA and IgM and the formation of a medicament therefrom
#372Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction
#373Method for cloning cognate antibodies
#374Methods of identifying a compound that increases or decreases the interaction of Hn-33 with synaptotagmin II
#375Therapeutic Clostridium difficile antibody compositions
#376Fluorescent single chain antibody and its use in detection of analytes
#377DETERMINING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY USING BOTULINUM TOXIN A PEPTIDES
#378HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
#379Synthesis of human secretory IgA for the treatment of associated diseases
#380Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
#381Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
#382Inhibition of secretion from non-neuronal cells
#383Treatment for bacterial infections
#384Combination Therapy for Gastroenteric Diseases Caused by Microorganisms
#385Soluble recombinant botulinum toxin proteins
#386Immunization Against Clostridium Difficile Disease
#387Recombinant chimeric human anti-botulinum antibodies
#388BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
#389BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
#390BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
#391ANTIBODY PRODUCTION IN FARM ANIMALS
#392Method for linking sequences of interest
#393Vaccine delivery
#394Clostridium difficile focussed antibodies
#395Compositions comprising large and small binding fragments of antibodies against the same toxin
#396Recombinant bivalent monospecific immunoglobulin having at least two variable fragments of heavy chains of an immunoglobulin devoid of light chains
#397Antibodies against type A botulinum neurotoxin
#398Compositions against chicken coccidiosis
#399Human antibodies derived from immunized xenomice
#400Immunization against clostridium difficile disease
#401Human antibodies derived from immunized xenomice
#402Antibodies against toxins and uses thereof
#403Soluble recombinant botulinum toxin proteins
#404Colostrum-based composition
#405Antibody production in farm animals
#406Use of a tag to enrich polypeptides libraries
#407Look-through mutagenesis
#408Host cells containing multiple integrating vectors
#409Generation of xenogeneic antibodies
#410Expression vectors
#411Human antibodies derived from immunized xenomice
#412Botulinum antitoxin compositions and methods
#413Multi-functional antibodies
#414C.difficile toxin B CROP domain peptides, antibodies and complexes thereof